1[1]Neaton J D, Wentworth D. Serum cholesterol, blood presure,cigarette smoking, and death from coronary heart disease.Overall findings and differences by age for 316 099 white men.Multiple Risk Factor Intervention Trial Research Group[J].Arch Intern Med, 1992,152 (1): 56-64.
2[2]Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in4 444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study[J]. Lancet, 1994,344(8934): 1383-1389.
3[4]The Long-Term Intervention with Pravastatin in Ischemic Disease(LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J].N Engl J Med, 1998,339(19) :1349-1357.
4[5]Fric M H, Elo O, Haapa K, et al . Helsinki Heart Study:primary-prevertion trial with gemfibrzil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease[J]. N Engl J Med, 1987,317(20) :1237-1245.
5[6]Rubins H B, Robins S J, Collins D, et al . Gemfibrozil for the secondary prevention or coronary heart disease in men with olw levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Trial Study Group[J].N Engl J Med, 1999,341(6) :410-418.
6[7]Canner P L, Berge K G, Wenger N K, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin[J]. J Am Coll Cardiol, 1986,8(6): 1245-1255.
7[8]Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel Ⅲ)[J].JAMA, 2001,285(19): 2486-2497.
8[9]Guyton J R, Capuzzi D M. Treatment of hyperlipidemia with combined niacin-statin regimens[J]. Am J Cardiol, 1998,82(12A): 82U-86U.
9[10]Murdock D K, Murdock A K, Murkock R W, et al . Longterm safety and efficacy of combination gemfibrozil and HMGCoA reductase inhibitors for the treatment of mixed lipid disorders[J]. Am Heart J, 1999,138(1 Pt 1):151-155.
10[11]Iliadis E A, Rosenson R S. Long-term safety of pravastatingemfibrozil therapy in mixed hyperlipidemia[J]. Clin Cardiol,1999,22 (1): 25-28.
3Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipidlowering drugs[J]. JAMA, 2004, 292(21): 2 585.
4Pasternak RC, Smith SC, Bairey - Merz CN, et al. ACC/AHA/NALBI clinical adevisory on the use and safety of statins[J]. Circulation, 2002, 106:1 024.
5Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel Ⅲ )[J]. JAMA, 2001, 285:2 486.
6Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke [ J] . Arch Neurol, 2004, 61(6): 889.
7Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2-mediated hepatic uptake and CYP2C8 - mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug- drug interaction between cerivastatin and gemfibrozil[J]. J Pharmacol Exp Ther , 2004, 311(1): 228.
8Prueksaritanont T, Zhao J J, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins[J]. J Pharmacol Exp Ther, 2002, 301(3): 1 042.
9Pauciullo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia ( FACT study ) [ J ]. Atherosclerosis,2000, 150(2) :429.
10Ellen RL, Mc Pherson R. Long - term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia[J]. Am J Cardiol, 1998, 81 (4A): 60B.
